SLC5A2 and diabetes mellitus: Based on this evidence, the 2022 update of the KDIGO guidelines for diabetes management in chronic kidney disease recommend the initiation of treatment with an SGLT-2-inhibitor in people with DM and CKD having an eGFR of at least ≥20 mL/min/1.73 m2 [86].